BRAF and cholangiocarcinoma: This oral combination was evaluated in the phase II ROAR basket trial with a subset of 43 advanced cholangiocarcinoma patients with previous systemic therapy and BRAF V600E mutations, demonstrating an overall response rate of 51% [57].